{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=A+PROTEIN+level&page=52",
    "query": {
      "intervention": "A PROTEIN level",
      "page": 52
    },
    "page_size": 10
  },
  "pagination": {
    "page": 52,
    "page_size": 10,
    "total_count": 1386,
    "total_pages": 139,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=A+PROTEIN+level&page=53&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=A+PROTEIN+level&page=51&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-22T06:25:23.826Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02073097",
      "title": "Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Contiguous Stage II Adult Diffuse Large Cell Lymphoma",
        "Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma",
        "Stage I Adult Diffuse Large Cell Lymphoma",
        "Stage III Adult Diffuse Large Cell Lymphoma",
        "Stage IV Adult Diffuse Large Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Carfilzomib",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Vincristine sulfate",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Pegfilgrastim",
          "type": "DRUG"
        },
        {
          "name": "Acyclovir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2015-01-28",
      "completion_date": "2023-06-29",
      "has_results": true,
      "last_update_posted_date": "2024-05-29",
      "last_synced_at": "2026-10-22T06:25:23.826Z",
      "location_count": 3,
      "location_summary": "Buffalo, New York • Cleveland, Ohio",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02073097"
    },
    {
      "nct_id": "NCT05824975",
      "title": "A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Metastatic Solid Tumor",
        "Soft Tissue Sarcoma (STS)",
        "Platinum-resistant Ovarian Cancer (PROC)",
        "Hepatocellular Carcinoma (HCC)",
        "Colorectal Cancer (CRC)",
        "HER2 Negative Breast Cancer",
        "Cutaneous Melanoma",
        "Renal Cell Carcinoma (RCC)"
      ],
      "interventions": [
        {
          "name": "GI-102 subcutaneous (SC)",
          "type": "DRUG"
        },
        {
          "name": "GI-102",
          "type": "DRUG"
        },
        {
          "name": "doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "eribulin",
          "type": "DRUG"
        },
        {
          "name": "trastuzumab deruxtecan (T-DXd)",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GI Innovation, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 358,
      "start_date": "2023-05-30",
      "completion_date": "2027-04-24",
      "has_results": false,
      "last_update_posted_date": "2024-11-25",
      "last_synced_at": "2026-10-22T06:25:23.826Z",
      "location_count": 5,
      "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 2 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05824975"
    },
    {
      "nct_id": "NCT05917522",
      "title": "Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kidney Transplant"
      ],
      "interventions": [
        {
          "name": "Abatacept",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Standard of Care at US Transplant Centers",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 800,
      "start_date": "2023-12-07",
      "completion_date": "2029-07",
      "has_results": false,
      "last_update_posted_date": "2026-03-23",
      "last_synced_at": "2026-10-22T06:25:23.826Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 11 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05917522"
    },
    {
      "nct_id": "NCT05994794",
      "title": "Role of a Dietary Supplement in Lowering SAH in Healthy Adults With Elevated Plasma SAH and Normal Homocysteine Levels",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Elevated S-adenosylhomocysteine"
      ],
      "interventions": [
        {
          "name": "Alpha-GPC, Creatine and Ashwagandha (Sensoril®)",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "Standard Process Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "30 Years to 75 Years"
      },
      "enrollment_count": 40,
      "start_date": "2022-12-09",
      "completion_date": "2023-10-05",
      "has_results": false,
      "last_update_posted_date": "2024-03-07",
      "last_synced_at": "2026-10-22T06:25:23.826Z",
      "location_count": 1,
      "location_summary": "South Gate, California",
      "locations": [
        {
          "city": "South Gate",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05994794"
    },
    {
      "nct_id": "NCT03254277",
      "title": "3BNC117-LS First-in-Human Phase 1 Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "3BNC117-LS",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rockefeller University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 43,
      "start_date": "2017-09-13",
      "completion_date": "2020-12-31",
      "has_results": true,
      "last_update_posted_date": "2026-05-20",
      "last_synced_at": "2026-10-22T06:25:23.826Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03254277"
    },
    {
      "nct_id": "NCT05657301",
      "title": "Safety and Tolerability of KH631 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "KH631",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Chengdu Origen Biotechnology Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 25,
      "start_date": "2023-10-16",
      "completion_date": "2027-09",
      "has_results": false,
      "last_update_posted_date": "2025-12-31",
      "last_synced_at": "2026-10-22T06:25:23.826Z",
      "location_count": 7,
      "location_summary": "Phoenix, Arizona • Lemont, Illinois • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Lemont",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Reno",
          "state": "Nevada"
        },
        {
          "city": "Cherry Hill",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05657301"
    },
    {
      "nct_id": "NCT03326752",
      "title": "Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Non Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "DV281",
          "type": "DRUG"
        },
        {
          "name": "Breath Actuated Nebulizer",
          "type": "DEVICE"
        },
        {
          "name": "DV281 (RP2D)",
          "type": "DRUG"
        },
        {
          "name": "Approved Anti-PD-1 Inhibitor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Dynavax Technologies Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2017-09-20",
      "completion_date": "2019-09-19",
      "has_results": false,
      "last_update_posted_date": "2020-06-17",
      "last_synced_at": "2026-10-22T06:25:23.826Z",
      "location_count": 6,
      "location_summary": "La Jolla, California • Santa Monica, California • Minneapolis, Minnesota + 3 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03326752"
    },
    {
      "nct_id": "NCT00135811",
      "title": "Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Glomerulosclerosis, Focal"
      ],
      "interventions": [
        {
          "name": "Cyclosporin",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate mofetil and Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "2 Years to 40 Years"
      },
      "enrollment_count": 192,
      "start_date": "2004-11",
      "completion_date": "2009-11",
      "has_results": true,
      "last_update_posted_date": "2026-09-18",
      "last_synced_at": "2026-10-22T06:25:23.826Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00135811"
    },
    {
      "nct_id": "NCT05104567",
      "title": "A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Oesophageal Squamous Cell Carcinoma",
        "Gastric Cancer",
        "Hepatocellular Carcinoma",
        "Colorectal Cancer",
        "Oesophageal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "THOR-707",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 138,
      "start_date": "2021-12-09",
      "completion_date": "2024-09-09",
      "has_results": true,
      "last_update_posted_date": "2025-09-24",
      "last_synced_at": "2026-10-22T06:25:23.826Z",
      "location_count": 3,
      "location_summary": "Duarte, California • Orlando, Florida • Seattle, Washington",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05104567"
    },
    {
      "nct_id": "NCT04225234",
      "title": "Sustaining the Reach of a Scalable Weight Loss Intervention Through Financial Incentives",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Overweight and Obesity"
      ],
      "interventions": [
        {
          "name": "Financial incentives",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Nebraska",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 119,
      "start_date": "2019-08-20",
      "completion_date": "2021-08-31",
      "has_results": false,
      "last_update_posted_date": "2024-09-05",
      "last_synced_at": "2026-10-22T06:25:23.826Z",
      "location_count": 1,
      "location_summary": "Omaha, Nebraska",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04225234"
    }
  ]
}